ImmunoGen, Inc. (IMGN)

NASDAQ: IMGN · IEX Real-Time Price · USD
5.39
+0.24 (4.66%)
Jul 7, 2022 12:27 PM EDT - Market open
4.66%
Market Cap 1.19B
Revenue (ttm) 92.23M
Net Income (ttm) -129.40M
Shares Out 220.54M
EPS (ttm) -0.59
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,630,705
Open 5.14
Previous Close 5.15
Day's Range 5.07 - 5.45
52-Week Range 3.10 - 7.77
Beta 1.17
Analysts Buy
Price Target 12.24 (+127.1%)
Earnings Date Jul 29, 2022

About IMGN

ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in c... [Read more...]

Industry Biotechnology
IPO Date Nov 16, 1989
CEO Mark Enyedy
Employees 106
Stock Exchange NASDAQ
Ticker Symbol IMGN
Full Company Profile

Financial Performance

In 2021, ImmunoGen's revenue was $69.86 million, a decrease of -47.20% compared to the previous year's $132.30 million. Losses were -$139.30 million, 213.9% more than in 2020.

Financial Statements

Analyst Forecast

According to 16 analysts, the average rating for IMGN stock is "Buy." The 12-month stock price forecast is 12.24, which is an increase of 127.09% from the latest price.

Price Target
$12.24
(127.09% upside)
Analyst Consensus: Buy
Stock Forecasts

News

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ImmunoGen (IMGN) Enters New Collaboration to Boost ADC Pipeline

ImmunoGen (IMGN) inks a collaboration deal with privately-held Oxford BioTherapeutics to develop novel antibody-drug conjugates by complementing each other's proprietary technologies.

ImmunoGen Announces Research Collaboration with Oxford BioTherapeutics to Develop Novel Antibody-Drug Conjugates

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Research Collaboration with Oxford BioTherapeutics to Develop Novel Antibody-Drug Conjugates

ImmunoGen Presents Additional Efficacy and Safety Analyses Evaluating Mirvetuximab Soravtansine in Ovarian Cancer at ...

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Presents Additional Efficacy and Safety Analyses Evaluating Mirvetuximab Soravtansine in Ovarian Cancer at ASCO

ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences

ImmunoGen (IMGN) Ovarian Cancer Drug BLA Gets Priority Review

ImmunoGen (IMGN) gets priority review from the FDA for the BLA seeking approval for its lead candidate, mirvetuximab soravtansine, for treating platinum-resistant ovarian cancer.

What's Going On With ImmunoGen Shares Today?

ImmunoGen, Inc. (NASDAQ: IMGN) shares are trading flat at $3.57 after the company's Biologics License Application to treat ovarian cancer was accepted by the FDA with priority review. ImmunoGen's BLA ac...

ImmunoGen's stock is up 12% after the FDA accepts application for new ovarian-cancer therapy

Shares of ImmunoGen Inc. IMGN, +1.42% jumped 12.0% in premarket trading on Monday after the company said the Food and Drug Administration accepted an application for its experimental ovarian-cancer trea...

ImmunoGen Announces Acceptance of Biologics License Application for Mirvetuximab Soravtansine in Ovarian Cancer by US...

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Acceptance of Biologics License Application for Mirvetuximab Soravtansine in Ovarian Cancer by US FDA with Priority Review

ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming H.C. Wainwright Global Investment Conference

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming H.C. Wainwright Global Investment Conference

ImmunoGen (IMGN) Q1 Earnings and Sales Outpace Estimates

ImmunoGen (IMGN) reports a narrower-than-expected loss for first-quarter 2022. It also beats revenue estimates.

ImmunoGen (IMGN) Reports Q1 Loss, Tops Revenue Estimates

ImmunoGen (IMGN) delivered earnings and revenue surprises of 52.38% and 56.39%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

ImmunoGen Reports Recent Progress and First Quarter 2022 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Reports Recent Progress and First Quarter 2022 Financial Results

ImmunoGen Announces Conference Call to Discuss Its First Quarter 2022 Operating Results

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Conference Call to Discuss Its First Quarter 2022 Operating Results

Is ImmunoGen Stock a Bargain After Dropping 39%?

It takes more than a price drop to make a bargain.

ImmunoGen Announces Webcast of Panel Discussion at Upcoming Canaccord Genuity Horizons in Oncology Virtual Conference

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Webcast of Panel Discussion at Upcoming Canaccord Genuity Horizons in Oncology Virtual Conference

ImmunoGen (IMGN) Files BLA for Lead Drug in Ovarian Cancer

ImmunoGen (IMGN) seeks accelerated approval from the FDA for its lead candidate, mirvetuximab soravtansine, in previously treated platinum-resistant ovarian cancer. This pushes the stock price up.

ImmunoGen Submits Biologics License Application to the US Food and Drug Administration for Mirvetuximab Soravtansine ...

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Submits Biologics License Application to the US Food and Drug Administration for Mirvetuximab Soravtansine in Ovarian Cancer

Why Coinbase and Immunogen Led the Nasdaq Lower Monday

Markets were jittery following troubling comments from Fed chair Jerome Powell.

Other symbols: COIN

Why Are ImmunoGen Shares Trading Lower Today

ImmunoGen Inc (NASDAQ: IMGN) shared full results from the SORAYA trial evaluating mirvetuximab in folate receptor alpha (FRα)-high platinum-resistant ovarian cancer patients, previously treated with Roc...

ImmunoGen Presents Full Results from Positive Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer at ...

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Presents Full Results from Positive Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer at SGO Annual Meeting

ImmunoGen to Present Full Results from SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer at the Society of ...

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen to Present Full Results from SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer at Society of Gynecologic Oncology Annual Meeting

ImmunoGen (IMGN) Q4 Earnings and Sales Outpace Estimates

ImmunoGen (IMGN) reports a narrower-than-expected loss for fourth-quarter 2021. It also beats revenue estimates.

ImmunoGen (IMGN) Reports Q4 Loss, Tops Revenue Estimates

ImmunoGen (IMGN) delivered earnings and revenue surprises of 5.56% and 6.96%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

ImmunoGen Reports Recent Progress and 2021 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Reports Recent Progress and 2021 Financial Results